Lilly Ventures

Lilly Ventures is the corporate venture capital arm of Eli Lilly and Company, based in Indianapolis, Indiana, and responsible for life science investing across North America and Europe. The fund manages approximately $200 million and operates as a therapeutically agnostic investor, backing companies from early to expansion stage across biotechnology, healthcare IT, and medical technology. It leads rounds and maintains a team of five professionals dedicated to identifying companies that can advance Lilly's drug discovery pipeline while also generating strong financial returns. In January 2025, Eli Lilly announced a landmark $500 million partnership with Andreessen Horowitz to create a new AI-focused biotech venture fund, signaling a major push into AI-driven drug development. The fund has made 84 investments and achieved an exceptional exit record of 36 exits, including 8 NASDAQ IPOs: BioAge Labs reached a $615 million market cap in September 2024, Kymeratx achieved an $863 million market cap, and Coherus Biosciences, Sutro Biopharma, and Protagonist Therapeutics have also gone public. The portfolio has also seen 19 acquisitions. Active portfolio companies include Insilico Medicine, an AI drug discovery firm that received Lilly Ventures' most recent investment in June 2025, alongside basys.ai and Evox Therapeutics. The fund also separately manages a $300 million Social Impact Venture Capital Portfolio targeting investments with measurable patient and societal benefit. Lilly Ventures operates as part of a broader Eli Lilly innovation ecosystem that includes Lilly Gateway Labs and Lilly ExploR&D, allowing portfolio companies to access laboratory infrastructure, scientific talent, and Lilly's global clinical and commercial networks. The fund's strategic alignment with Lilly's therapeutic priorities gives portfolio companies meaningful potential pathways to partnership and acquisition.